Neurology® Podcast

1) Olfactory dysfunction predicting early transition to Lewy body disease in idiopathic RBD and 2) Topic of the month: Autoimmune and paraneoplastic encephalitis. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Binit Shah interviews Dr. Werner Poewe about his paper on olfactory dysfunction predicting early transition to Lewy body disease in idiopathic RBD. Dr. Adam Numis is reading our e-Pearl of the week about Fragile X tremor ataxia syndrome. In the next part of the podcast Dr. Stacy Clardy interviews Dr. Josep Dalmau about other recently described antibodies associated with autoimmune encephalitis. The participants had nothing to disclose except Drs. Poewe, Numis and Dalmau.Dr. Poewe has received consultancy and lecture fees from Abbott, AstraZeneca, Teva Pharmaceutical Industries Ltd, Novartis, GlaxoSmithKline, Boehringer Ingelheim, UCB, Orion Pharma Ltd., and Merck Serono in relation to clinical drug development programs for Parkinson disease; has received research support from the Michael J. Fox Foundation; receives royalties from the publications of the books: Therapeutics of Parkinson's disease and other movement disorders, Non-motor symptoms of Parkinson's disease and Parkinson-syndrome und andere Bewegungsstorungen.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Dalmau serves as an editorial board member of Neurology® and UptoDate; serves as Editor-in-Chief of Neurology® Neuroimmunology and Neuroimflammation; is a consultant for Advance Medical; receives royalties for the following patents: Patent Ma2 autoantibody test, Patent NMDAR autoantibody test, patent application for the use of GABA(B) receptor, DPPX and IgLON5 autoantibody tests; received license fee payments for DPPX and IgLON5 autoantibody tests from Euroimmun; receives research support from Euroimmun, ISCIII, and the NIH.

1) Non-cognitive symptoms of early Alzheimer disease and 2) Topic of the month: Autoimmune and paraneoplastic encephalitis. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interviews Dr. Catherine Roe about her paper on non-cognitive symptoms of early Alzheimer disease. Dr. Adam Numis is reading our e-Pearl of the week about cannabidiol in the treatment of epilepsy. In the next part of the podcast Dr. Stacy Clardy interviews Dr. Josep Dalmau about the topic of NMDA receptor encephalitis. The participants had nothing to disclose except Drs. Burns, Roe, Numis and Dalmau.Dr. Jeff Burns serves on the editorial board for Journal of Alzheimer's Disease; receives royalties for the publications of Early diagnosis and treatment of mild cognitive impairment and Dementia: An atlas of investigation and diagnosis; is a consultant for PRA International and receives research support from the NIH, Alzheimer's Drug Discovery Foundation, Elan, Janssen Pharmaceuticals Inc., Wyeth, Pfizer Inc, Novartis Pharmaceuticals Ltd, Danone, Avid Radiopharmaceuticals, Merck Serono and for clinical trials.Dr. Roe receives salary support from the NIH, the Longer Life Foundation, the Charles and Joanne Knight Alzheimer Research Initiative of the Knight Alzheimer's disease Research Center, The Farrell Family Research Fund, and F. Simmons and O. Mohan; receives research support from the Charles and Joanne Knight Alzheimer Research Initiative of the Knight Alzheimer's disease Research Center, the Longer Life Foundation, The Farrell Family Research Fund, and F. Simmons and O. Mohan.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Dalmau serves as an editorial board member of Neurology® and UptoDate; serves as Editor-in-Chief of Neurology® Neuroimmunology and Neuroimflammation; is a consultant for Advance Medical; receives royalties for the following patents: Patent Ma2 autoantibody test, Patent NMDAR autoantibody test, patent application for the use of GABA(B) receptor, DPPX and IgLON5 autoantibody tests; received license fee payments for DPPX and IgLON5 autoantibody tests from Euroimmun; receives research support from Euroimmun, ISCIII, and the NIH.

1) Optimal achieved blood pressure in acute intracerebral hemorrhage and 2) Topic of the month: Autoimmune and paraneoplastic encephalitis. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mike Brogan interviews Dr. Craig Anderson about his paper on the optimal achieved blood pressure in acute intracerebral hemorrhage. Dr. Adam Numis is reading our e-Pearl of the week about neuropathy in Fabry disease. In the next part of the podcast Dr. Stacy Clardy interviews Dr. Josep Dalmau about the topic of autoimmune and paraneoplastic encephalitis and how recent discoveries have changed our understanding of these disorders. The participants had nothing to disclose except Drs. Anderson, Numis and Dalmau.Dr. Anderson serves as an editorial board member of Stroke, Cerebrovascular Diseases, and Medical Journal of Australia; receives honoraria from serving on the scientific advisory board for Pfizer Inc and The Medicines Company; receives funding for travel from Takeda China and Covidien; and receives research support from the National Health and Medical Research Council (NHMRC) of Australia.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Dalmau serves as an editorial board member of Neurology® and UptoDate; serves as Editor-in-Chief of Neurology® Neuroimmunology and Neuroimflammation; is a consultant for Advance Medical; receives royalties for the following patents: Patent Ma2 autoantibody test, Patent NMDAR autoantibody test, patent application for the use of GABA(B) receptor, DPPX and IgLON5 autoantibody tests; received license fee payments for DPPX and IgLON5 autoantibody tests from Euroimmun; receives research support from Euroimmun, ISCIII, and the NIH.

Movement Disorder Emergencies. Lesson of the Week interviews from November 2014.

1) Causes, management and predictors of outcome in acute encephalitis and 2) Topic of the month: Myelopathy due to systemic disease. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mike Brogan interviews Dr. Alejandro Rabinstein about his paper on the causes, management and predictors of outcome in acute encephalitis. Dr. Sarah Wesley is reading our e-Pearl of the week about Charcot-Marie-Tooth. In the next part of the podcast Dr. Ted Burns interviews Dr. Steven L. Lewis about the topic of myelopathy due to systemic disease: chemo, mets, AMN, organ/failure/dysfxn and extramed hemato. The participants had nothing to disclose except Drs. Canning, Wesley, Burns and Lewis.Dr. Rabinstein serves as an Associate Editor of Neurocritical Care, serves as an editorial board member of Neurology®, served on the safety monitoring board for the PREVAIL trial; receives royalties from the publication of the books Practical Neuroimaging in Stroke and What To Do? Neurocritical Care and receives research support from DJO Global.Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc.Dr. Lewis serves as CME Section Co-Editor for Neurology® and as Editor in Chief for Continuum: Lifelong Learning in Neurology®; received royalties for book authorship and editorship from the publishers Wolters Kluwer and Wiley- Blackwell.

1) Exercise for falls prevention in Parkinson disease and 2) Topic of the month: Myelopathy due to systemic disease. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Michele Fullard interviews Dr. Colleen Canning about her paper on exercise for falls prevention in Parkinson disease. Dr. Sarah Wesley is reading our e-Pearl of the week about subacute sclerosing panencephalitis. In the next part of the podcast Dr. Ted Burns interviews Dr. Steven L. Lewis about the topic of myelopathy due to systemic disease: drugs, toxins, vitamin and minerals. The participants had nothing to disclose except Drs. Canning, Wesley, Burns and Lewis.Dr. Canning received funding for travel expenses and honorarium from the Movement Disorders Society, Singapore General Hospital, Australian and New Zealand Falls Prevention Society; receives research support from the Australian Government National Health and Medical Research Council, Parkinson's NSW and Harry Secomb Foundation.Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc.Dr. Lewis serves as CME Section Co-Editor for Neurology® and as Editor in Chief for Continuum: Lifelong Learning in Neurology®; received royalties for book authorship and editorship from the publishers Wolters Kluwer and Wiley- Blackwell.

1) Reduced trigeminovascular cyclicity in patients with menstrually-related migraine and 2) Topic of the month: Myelopathy due to systemic disease. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Antoinette Maassen van den Brink about her paper on reduced trigeminovascular cyclicity in patients with menstrually-related migraine. Dr. Sarah Wesley is reading our e-Pearl of the week about tauopathies. In the next part of the podcast Dr. Ted Burns interviews Dr. Steven L. Lewis about the topic of myelopathy due to systemic disease: infections. The participants had nothing to disclose except Drs. Southerland, Maassen van den Brink, Wesley, Burns and Lewis.Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc.Dr. Maassen van den Brink received support for congress visits from Menarini Group; receives research support from Netherlands Organization for Scientific Research, Dutch Brain Foundation, Netherlands Heart Foundation, MAP Pharmaceuticals, Inc. and Allergan, Inc.Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc.Dr. Lewis serves as CME Section Co-Editor for Neurology® and as Editor in Chief for Continuum: Lifelong Learning in Neurology®; received royalties for book authorship and editorship from the publishers Wolters Kluwer and Wiley- Blackwell.

Neuro-infectious diseases part II. Lesson of the Week interviews from October 2014.

1) Optimal combination of secondary prevention drug treatment and stroke outcomes and 2) Topic of the month: Myelopathy due to systemic disease. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Bruce Ovbiagele about his paper on the optimal combination of secondary prevention drug treatment and stroke outcomes. Dr. Sarah Wesley is reading our e-Pearl of the week about persistent cryptococcal meningitis. In the next part of the podcast Dr. Ted Burns interviews Dr. Steven L. Lewis about the topic of myelopathy due to systemic disease: autoimmune disorders. The participants had nothing to disclose except Drs. Southerland, Ovbiagele, Wesley, Burns and Lewis.Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc.Dr. Ovbiagele serves as an Assistant Editor of Stroke; serves as an Associate Editor of the Journal of Neurological Sciences; serves on the editorial board of the Journal of Stroke and Cerebrovascular Diseases and receives research support from the NIH.Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc.Dr. Lewis serves as CME Section Co-Editor for Neurology® and as Editor in Chief for Continuum: Lifelong Learning in Neurology®; received royalties for book authorship and editorship from the publishers Wolters Kluwer and Wiley- Blackwell.

1) Physician burnout: A neurologic crisis and 2) Topic of the month: Living legend interviews: A career as a neurologist. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Bruce Sigsbee about his paper on physician burnout. Dr. James Addington is reading our e-Pearl of the week about colloid cysts. In the next part of the podcast Dr. Stacey Clardy interviews Dr. Josep Dalmau about his career as a neurologist. The participants had nothing to disclose except Drs. Burns, Sigsbee, Addington and Dalmau.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc.Dr. Sigsbee is a consultant for a non-profit, the American Academy of Neurology, on healthcare policy and advocacy.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Dalmau serves as an editorial board member of Neurology® and UptoDate; serves as Editor-in-Chief of Neurology® Neuroimmunology and Neuroimflammation; is a consultant for Advance Medical; receives royalties for the following patents: Patent Ma2 autoantibody test, Patent NMDAR autoantibody test, patent application for the use of GABA(B) receptor, DPPX and IgLON5 autoantibody tests; received license fee payments for DPPX and IgLON5 autoantibody tests from Euroimmun; receives research support from Euroimmun, ISCIII, and the NIH.